FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:SUZ12-LRRC37A

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: SUZ12-LRRC37A
FusionPDB ID: 88241
FusionGDB2.0 ID: 88241
HgeneTgene
Gene symbol

SUZ12

LRRC37A

Gene ID

23512

105376839

Gene nameSUZ12 polycomb repressive complex 2 subunituncharacterized LOC105376839
SynonymsCHET9|IMMAS|JJAZ1LRRC37A
Cytomap

17q11.2

17q21.31

Type of geneprotein-codingncRNA
Descriptionpolycomb protein SUZ12chET 9 proteinchromatin precipitated E2F target 9 proteinjoined to JAZF1 proteinsuppressor of zeste 12 protein homologleucine rich repeat containing 37A
Modification date2020031320200313
UniProtAcc

Q15022

Main function of 5'-partner protein: FUNCTION: Polycomb group (PcG) protein. Component of the PRC2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene (PubMed:15225548, PubMed:15231737, PubMed:15385962, PubMed:16618801, PubMed:17344414, PubMed:18285464, PubMed:28229514, PubMed:29499137, PubMed:31959557). The PRC2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems (PubMed:12435631, PubMed:12351676, PubMed:15385962, PubMed:15099518, PubMed:15225548, PubMed:15684044, PubMed:16431907, PubMed:18086877, PubMed:18285464). Genes repressed by the PRC2 complex include HOXC8, HOXA9, MYT1 and CDKN2A (PubMed:15231737, PubMed:16618801, PubMed:17200670, PubMed:31959557). {ECO:0000269|PubMed:12351676, ECO:0000269|PubMed:12435631, ECO:0000269|PubMed:15099518, ECO:0000269|PubMed:15225548, ECO:0000269|PubMed:15231737, ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:15684044, ECO:0000269|PubMed:16431907, ECO:0000269|PubMed:16618801, ECO:0000269|PubMed:17200670, ECO:0000269|PubMed:17344414, ECO:0000269|PubMed:18086877, ECO:0000269|PubMed:18285464, ECO:0000269|PubMed:28229514, ECO:0000269|PubMed:29499137, ECO:0000269|PubMed:31959557}.

O60309

Main function of 5'-partner protein:
Ensembl transtripts involved in fusion geneENST idsENST00000322652, ENST00000580398, 
ENST00000320254, ENST00000393465, 
ENST00000496930, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score15 X 12 X 10=18007 X 7 X 6=294
# samples 157
** MAII scorelog2(15/1800*10)=-3.58496250072116
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/294*10)=-2.0703893278914
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: SUZ12 [Title/Abstract] AND LRRC37A [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: SUZ12 [Title/Abstract] AND LRRC37A [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)SUZ12(30303633)-LRRC37A(44405757), # samples:1
Anticipated loss of major functional domain due to fusion event.SUZ12-LRRC37A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
SUZ12-LRRC37A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
SUZ12-LRRC37A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
SUZ12-LRRC37A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:30303633/chr17:44405757)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across SUZ12 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across LRRC37A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000322652SUZ12chr1730303633+ENST00000496930LRRC37Achr1744405757+326511463731951052
ENST00000322652SUZ12chr1730303633+ENST00000393465LRRC37Achr1744405757+30551146373000987
ENST00000322652SUZ12chr1730303633+ENST00000320254LRRC37Achr1744405757+326711463731951052
ENST00000580398SUZ12chr1730303633+ENST00000496930LRRC37Achr1744405757+314710281083077989
ENST00000580398SUZ12chr1730303633+ENST00000393465LRRC37Achr1744405757+293710281082882924
ENST00000580398SUZ12chr1730303633+ENST00000320254LRRC37Achr1744405757+314910281083077989

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000322652ENST00000496930SUZ12chr1730303633+LRRC37Achr1744405757+0.0007053790.99929464
ENST00000322652ENST00000393465SUZ12chr1730303633+LRRC37Achr1744405757+0.0009438910.99905616
ENST00000322652ENST00000320254SUZ12chr1730303633+LRRC37Achr1744405757+0.0007180430.99928194
ENST00000580398ENST00000496930SUZ12chr1730303633+LRRC37Achr1744405757+0.0006897770.99931026
ENST00000580398ENST00000393465SUZ12chr1730303633+LRRC37Achr1744405757+0.0010854990.9989145
ENST00000580398ENST00000320254SUZ12chr1730303633+LRRC37Achr1744405757+0.0007026470.9992974

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for SUZ12-LRRC37A

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
SUZ12chr1730303633LRRC37Achr17444057571028306KTFVAQMTVFDKNRILPSHMACCLCQ
SUZ12chr1730303633LRRC37Achr17444057571146369KTFVAQMTVFDKNRILPSHMACCLCQ

Top

Potential FusionNeoAntigen Information of SUZ12-LRRC37A in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
SUZ12-LRRC37A_30303633_44405757.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B14:01NRILPSHM0.99930.78371220
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B14:02NRILPSHM0.99930.78371220
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B15:37NRILPSHM0.99320.55721220
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B39:06NRILPSHMA0.99650.78011221
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B14:01NRILPSHMA0.99320.76051221
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B14:02NRILPSHMA0.99320.76051221
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B39:06NRILPSHMAC0.96750.88381222
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C04:10VFDKNRIL0.99990.6796816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C04:07VFDKNRIL0.99990.683816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B39:12NRILPSHM0.99940.93631220
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C04:14VFDKNRIL0.99560.6687816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C12:16NRILPSHM0.96460.96571220
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B27:14NRILPSHMA0.99850.68131221
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:07TVFDKNRIL0.99820.9523716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B73:01NRILPSHMA0.99810.6981221
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C15:06TVFDKNRIL0.99780.8491716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:19TVFDKNRIL0.99770.979716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:08TVFDKNRIL0.99760.9078716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C15:04TVFDKNRIL0.99740.8193716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B39:12NRILPSHMA0.99030.91881221
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C04:06TVFDKNRIL0.98350.7152716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C08:04TVFDKNRIL0.9650.94716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C08:13TVFDKNRIL0.9650.94716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C12:12TVFDKNRIL0.90590.9111716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:13TVFDKNRIL0.87680.8888716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C02:06TVFDKNRIL0.87560.9004716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C06:03TVFDKNRIL0.86670.9924716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C12:04TVFDKNRIL0.86020.9928716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:29TVFDKNRIL0.82890.9197716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C01:17TVFDKNRIL0.82730.9063716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:05TVFDKNRIL0.78110.9592716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:14TVFDKNRIL0.75680.9563716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:19TVFDKNRIL0.70810.6253716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:27TVFDKNRIL0.68330.9539716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C01:30TVFDKNRIL0.68280.9315716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C12:16TVFDKNRIL0.67060.9579716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:95TVFDKNRIL0.63810.7188716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B73:01NRILPSHMAC0.98030.86431222
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B27:14KNRILPSHMA0.89110.71751121
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B73:01DKNRILPSHMA0.99610.84991021
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C04:01VFDKNRIL0.99990.683816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C18:01VFDKNRIL0.99990.7136816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C04:03VFDKNRIL0.99990.7276816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C06:06VFDKNRIL0.99910.9723816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C14:02VFDKNRIL0.99850.9171816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C14:03VFDKNRIL0.99850.9171816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:67VFDKNRIL0.99850.9813816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C04:04VFDKNRIL0.99720.7294816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:04VFDKNRIL0.99710.8992816
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:04TVFDKNRIL0.99820.9844716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:03TVFDKNRIL0.99820.9844716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C15:09TVFDKNRIL0.99740.8193716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C15:05TVFDKNRIL0.99720.8729716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C15:02TVFDKNRIL0.99670.8123716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:17TVFDKNRIL0.99650.9701716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:05TVFDKNRIL0.99620.9484716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:67TVFDKNRIL0.99460.9769716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:02TVFDKNRIL0.99250.9702716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B39:31NRILPSHMA0.99240.91841221
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C16:04TVFDKNRIL0.9880.9636716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C03:06TVFDKNRIL0.950.9861716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B07:13TVFDKNRIL0.94310.6279716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C12:03TVFDKNRIL0.92190.9722716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C06:06TVFDKNRIL0.91630.973716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C16:01TVFDKNRIL0.91610.9574716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C16:02TVFDKNRIL0.91010.9769716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C06:17TVFDKNRIL0.88640.9926716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C06:02TVFDKNRIL0.88640.9926716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:22TVFDKNRIL0.87740.712716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-A69:01TVFDKNRIL0.85950.6184716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:04TVFDKNRIL0.82990.9071716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C01:02TVFDKNRIL0.8250.9021716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-A25:01TVFDKNRIL0.81510.7359716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C12:02TVFDKNRIL0.7950.9608716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C02:10TVFDKNRIL0.750.9445716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C02:02TVFDKNRIL0.750.9445716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C06:08TVFDKNRIL0.68390.9763716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C07:01TVFDKNRIL0.62850.7055716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-B15:30TVFDKNRIL0.50610.9179716
SUZ12-LRRC37Achr1730303633chr17444057571146HLA-C17:01TVFDKNRIL0.20880.7458716

Top

Potential FusionNeoAntigen Information of SUZ12-LRRC37A in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
SUZ12-LRRC37A_30303633_44405757.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0405KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0409KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0417KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0424KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0429KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0430KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0445KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0448KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0457KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0477KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0480KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0483KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0484KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0486KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0487KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-0489KTFVAQMTVFDKNRI015
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1113VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1113FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1304VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1309VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1309FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1317VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1343VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1343FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1354VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1354FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1377VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1377FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1393VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1401VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1401FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1404VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1404FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1411VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1411FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1416VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1416FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1418VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1426VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1426FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1428VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1428FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1431VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1431FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1432VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1432FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1434VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1435VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1435FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1437VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1437FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1439VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1439FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1445VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1450VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1450FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1454VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1454FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1455VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1455FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1458VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1458FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1460VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1460FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1461VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1461FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1462VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1462FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1464VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1465VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1465FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1470VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1471VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1471FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1472VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1475VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1481VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1486VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1486FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1487VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1487FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1488VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1488FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1490VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1490FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1497VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1497FVAQMTVFDKNRILP217
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1499VAQMTVFDKNRILPS318
SUZ12-LRRC37Achr1730303633chr17444057571146DRB1-1499FVAQMTVFDKNRILP217

Top

Fusion breakpoint peptide structures of SUZ12-LRRC37A

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6051MTVFDKNRILPSHMSUZ12LRRC37Achr1730303633chr17444057571146

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of SUZ12-LRRC37A

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6051MTVFDKNRILPSHM-7.9962-8.1096
HLA-B14:023BVN6051MTVFDKNRILPSHM-5.70842-6.74372
HLA-B52:013W396051MTVFDKNRILPSHM-6.83737-6.95077
HLA-B52:013W396051MTVFDKNRILPSHM-4.4836-5.5189
HLA-A11:014UQ26051MTVFDKNRILPSHM-10.0067-10.1201
HLA-A11:014UQ26051MTVFDKNRILPSHM-9.03915-10.0745
HLA-A24:025HGA6051MTVFDKNRILPSHM-6.56204-6.67544
HLA-A24:025HGA6051MTVFDKNRILPSHM-5.42271-6.45801
HLA-B44:053DX86051MTVFDKNRILPSHM-7.85648-8.89178
HLA-B44:053DX86051MTVFDKNRILPSHM-5.3978-5.5112
HLA-A02:016TDR6051MTVFDKNRILPSHM-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of SUZ12-LRRC37A

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
SUZ12-LRRC37Achr1730303633chr17444057571021DKNRILPSHMATAAAAACAGGATCTTACCTAGCCATATGGCCTG
SUZ12-LRRC37Achr1730303633chr17444057571121KNRILPSHMAAAACAGGATCTTACCTAGCCATATGGCCTG
SUZ12-LRRC37Achr1730303633chr17444057571220NRILPSHMCAGGATCTTACCTAGCCATATGGC
SUZ12-LRRC37Achr1730303633chr17444057571221NRILPSHMACAGGATCTTACCTAGCCATATGGCCTG
SUZ12-LRRC37Achr1730303633chr17444057571222NRILPSHMACCAGGATCTTACCTAGCCATATGGCCTGCTG
SUZ12-LRRC37Achr1730303633chr1744405757716TVFDKNRILAGTATTTGATAAAAACAGGATCTTACC
SUZ12-LRRC37Achr1730303633chr1744405757816VFDKNRILATTTGATAAAAACAGGATCTTACC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
SUZ12-LRRC37Achr1730303633chr1744405757015KTFVAQMTVFDKNRIGACATTTGTTGCACAAATGACAGTATTTGATAAAAACAGGATCTT
SUZ12-LRRC37Achr1730303633chr1744405757217FVAQMTVFDKNRILPTGTTGCACAAATGACAGTATTTGATAAAAACAGGATCTTACCTAG
SUZ12-LRRC37Achr1730303633chr1744405757318VAQMTVFDKNRILPSTGCACAAATGACAGTATTTGATAAAAACAGGATCTTACCTAGCCA

Top

Information of the samples that have these potential fusion neoantigens of SUZ12-LRRC37A

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LGGSUZ12-LRRC37Achr1730303633ENST00000322652chr1744405757ENST00000320254TCGA-DU-5874

Top

Potential target of CAR-T therapy development for SUZ12-LRRC37A

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneLRRC37Achr17:30303633chr17:44405757ENST000003202546141583_160301701.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to SUZ12-LRRC37A

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to SUZ12-LRRC37A

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneSUZ12C0206727Nerve Sheath Tumors2CTD_human
HgeneSUZ12C0751689Peripheral Nerve Sheath Neoplasm2CTD_human
HgeneSUZ12C0751691Perineurioma2CTD_human
HgeneSUZ12C0001430Adenoma1CTD_human
HgeneSUZ12C0014170Endometrial Neoplasms1CTD_human
HgeneSUZ12C0017636Glioblastoma1CTD_human
HgeneSUZ12C0017638Glioma1CTD_human
HgeneSUZ12C0025202melanoma1CTD_human
HgeneSUZ12C0027809Neurilemmoma1CTD_human
HgeneSUZ12C0027830neurofibroma1CTD_human
HgeneSUZ12C0027962Melanocytic nevus1CTD_human
HgeneSUZ12C0042063Urogenital Abnormalities1GENOMICS_ENGLAND
HgeneSUZ12C0205646Adenoma, Basal Cell1CTD_human
HgeneSUZ12C0205647Follicular adenoma1CTD_human
HgeneSUZ12C0205648Adenoma, Microcystic1CTD_human
HgeneSUZ12C0205649Adenoma, Monomorphic1CTD_human
HgeneSUZ12C0205650Papillary adenoma1CTD_human
HgeneSUZ12C0205651Adenoma, Trabecular1CTD_human
HgeneSUZ12C0206630Endometrial Stromal Sarcoma1ORPHANET
HgeneSUZ12C0259783mixed gliomas1CTD_human
HgeneSUZ12C0265210Weaver syndrome1ORPHANET
HgeneSUZ12C0334588Giant Cell Glioblastoma1CTD_human
HgeneSUZ12C0476089Endometrial Carcinoma1CTD_human
HgeneSUZ12C0545053Advanced bone age1GENOMICS_ENGLAND
HgeneSUZ12C0555198Malignant Glioma1CTD_human
HgeneSUZ12C0557874Global developmental delay1GENOMICS_ENGLAND
HgeneSUZ12C0751374Schwannomatosis, Plexiform1CTD_human
HgeneSUZ12C1621958Glioblastoma Multiforme1CTD_human
HgeneSUZ12C1842581Abnormal corpus callosum morphology1GENOMICS_ENGLAND
HgeneSUZ12C1849265Overgrowth1GENOMICS_ENGLAND
HgeneSUZ12C3714756Intellectual Disability1GENOMICS_ENGLAND
HgeneSUZ12C4018871Abnormality of the respiratory system1GENOMICS_ENGLAND
HgeneSUZ12C4021664Abnormality of the abdominal wall1GENOMICS_ENGLAND
HgeneSUZ12C4021790Abnormality of the skeletal system1GENOMICS_ENGLAND